Quarterly report pursuant to Section 13 or 15(d)

ASSET PURCHASE AGREEMENT WITH KATANA (Details Narrative)

v3.22.2
ASSET PURCHASE AGREEMENT WITH KATANA (Details Narrative) - Asset Purchase Agreement [Member] - Katana Pharmaceuticals, Inc [Member]
Dec. 22, 2020
USD ($)
Asset Acquisition [Line Items]  
Consideration paid $ 700,000
Research and development costs $ 700,000